NASDAQ
27.07.26 | 22:00
60,12 US-Dollar
0,00 % 0,00
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.07. | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | 1 | Investing.com | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.07. | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | 360 | GlobeNewswire (Europe) | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| 09.07. | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | 2 | pulse2.com | ||
| 09.07. | Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug | 1 | Benzinga.com | ||
| 08.07. | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | 1 | Seeking Alpha | ||
| 08.07. | Tarsus Pharmaceuticals acquires iRenix for $75 million upfront | 2 | Investing.com | ||
| 08.07. | Tarsus Pharmaceuticals übernimmt iRenix für 75 Millionen US-Dollar Vorauszahlung | 4 | Investing.com Deutsch | ||
| 08.07. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07. | Leerverkäufer-Bericht schickt Tarsus-Aktie auf Talfahrt | 1 | Investing.com Deutsch | ||
| 29.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.05. | Tarsus taps John Cena for its latest Demodex blepharitis campaign | 2 | FiercePharma | ||
| 14.05. | Tarsus Pharmaceuticals, Inc: Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans | 2 | GlobeNewswire (USA) | ||
| 07.05. | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | 3 | Seeking Alpha | ||
| 07.05. | Tarsus Q1 2026 slides: XDEMVY sales surge 85%, $2B peak targeted | 2 | Investing.com | ||
| 06.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| 23.04. | Mizuho senkt Kursziel für Tarsus Pharmaceuticals wegen Umsatzaussichten auf 100 $ | 2 | Investing.com Deutsch | ||
| 31.03. | Tarsus doses first patient in Lyme disease prevention trial | 2 | Investing.com | ||
| 31.03. | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | 566 | GlobeNewswire (Europe) | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| 25.03. | Tarsus Pharmaceuticals: Mizuho hebt Kursziel nach Zulassung in China an | 5 | Investing.com Deutsch |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,470 | +1,34 % | Evotec Aktie: Dieser Indikator macht Hoffnung | Die Evotec Aktie hat vor einer Woche den nächsten schweren Rückschlag kassiert. Erneut enttäuschende Nachrichten des Hamburger Biotechnologie-Unternehmens schickten den Kurs auf Talfahrt, die am 14.... ► Artikel lesen | |
| MODERNA | 48,790 | -0,25 % | After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? | ||
| AMGEN | 334,70 | +1,15 % | Kleinzelliges Lungenkarzinom (SCLC): Hoch aggressiv und schwer behandelbar / Biotechnologieunternehmen Amgen engagiert sich in der Erforschung neuer Therapieansätze | München (ots) - Das kleinzellige Lungenkarzinom (Small Cell Lung Cancer, SCLC) ist eine der aggressivsten Formen von Lungenkrebs. Die Erkrankung schreitet besonders schnell voran, streut früh in andere... ► Artikel lesen | |
| NOVAVAX | 6,610 | +0,30 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 589,90 | +0,53 % | Here's What to Expect From Regeneron Pharmaceuticals' Next Earnings Report | ||
| VIKING THERAPEUTICS | 30,650 | -0,16 % | Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| KUROS BIOSCIENCES | 21,860 | -0,82 % | Was Insider bei Kuros Biosciences heute bereits wissen: Das Momentum spricht eine klare Sprache - Das sollten Sie jetzt wissen | ||
| ABIVAX | 111,70 | -0,36 % | EQS-News: ABIVAX: Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments | EQS-News: ABIVAX
/ Key word(s): Personnel
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
23.07.2026 / 22:05 CET/CEST
The issuer is... ► Artikel lesen | |
| MINDMAZE THERAPEUTICS | 0,169 | 0,00 % | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy | MindMaze Therapeutics Holding SA
/ Key word(s): Study
MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 4,270 | -0,81 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| DENALI THERAPEUTICS | 20,190 | -2,65 % | Denali Therapeutics Inc.: Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 | ||
| REVOLUTION MEDICINES | 165,05 | -0,36 % | Revolution Medicines: Bauchspeicheldrüsenkrebs-Durchbruch - Rekord-Zulassung in Sicht? | Die Biotech-Gesellschaft Revolution Medicines hat vor wenigen Monaten einen Durchbruch bei der Behandlung von Bauchspeicheldrüsenkrebs verbuchen können. In den USA und der EU laufen bereits die Zulassungsprozesse... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,028 | +5,76 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| INSMED | 92,60 | +0,48 % | This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 60,12 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.